Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11894382 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2ALMNADGAT1PTGDR2 | |
| SCHEMBL15535558 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2ALMNADGAT1PTGDR2 | |
| SCHEMBL569110 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2ALMNADGAT1PTGDR2 | |
| SCHEMBL569109 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2ALMNADGAT1PTGDR2 | |
| SCHEMBL4504501 | 0.84 | PTGDR2 (0.43) | SMN1; SMN2KMT2ALMNADGAT1PTGDR2 | |
| SCHEMBL2243013 | 0.83 | ALDH1A1 (0.40) | SMN1; SMN2KMT2ALMNADGAT1PTGDR2 | |
| SCHEMBL5034089 | 0.83 | KCNN4 (0.37) | SMN1; SMN2LMNAL3MBTL1KCNN4MAPT | |
| SCHEMBL14889830 | 0.83 | DGAT1 (0.42) | SMN1; SMN2KMT2ALMNADGAT1PTGDR2 | |
| SCHEMBL1173288 | 0.83 | DGAT1 (0.42) | SMN1; SMN2KMT2ALMNADGAT1PTGDR2 | |
| SCHEMBL246150 | 0.83 | DGAT1 (0.42) | SMN1; SMN2KMT2ALMNADGAT1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855469-B1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-2855469-B1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-3083644-B1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| US-9605006-B2 | 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605006-B2 | 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605006-B2 | 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN-LA ROCHE INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN-LA ROCHE INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN-LA ROCHE INC. (US) | 2016-11-03 | — | — | US | disclosed |
| EP-3083644-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | F. Hoffmann-La Roche AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-19 | — | — | US | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| US-8188079-B2 | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188079-B2 | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2012000933-A1 | 3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATEMENT OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000933-A1 | 3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATEMENT OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011080176-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-07-07 | — | — | WO | disclosed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | BACE1, BACE2, PSEN1 | SMN1; SMN2 611/4885KMT2A 3042/4885LMNA 1960/4885 |
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | SMN1; SMN2 664/4885KMT2A 2268/4885LMNA 3175/4885 |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | SMN1; SMN2 799/4885KMT2A 2406/4885LMNA 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.